UNSPSC 51162720: Letosteine

This classification denotes a mucolytic agent with the molecular formula C10H17NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6MVF9U95DW, chemically known as 4-thiazolidinecarboxylic acid, 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)- but more generally known as letosteine, which bears US NIH Compound Identifier 68707. European Medicines Agency schedules Letosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08442MIG. The term LETOSTEINE is an International Non-Proprietary Name.

UNSPSC 51162720 Letosteine is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone and related drug-intervention therapeutics, alongside over-the-counter pharmaceutical supplies through cooperative purchasing arrangements and direct county procurements. Recent solicitations show purchasing bodies acquiring naloxone in bulk quantities for community health and emergency-response initiatives, combined with generic multi-source pharmaceuticals and OTC products distributed through established wholesale supply chains. The issuing bodies include county health departments and state-level cooperative purchasing alliances coordinating multi-state pharmaceutical procurement.

Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB (IFB60459723LAS) with a response deadline of July 26, 2023, with quarterly deliveries to the county's community health facility. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with a response deadline of March 26, 2026. Contracts awarded under the MMCAP RFP become effective July 1, 2026, with vendor selection weighted primarily on price competitiveness (75 percent), compliance with administrative requirements (5 percent), EDI capability (5 percent), and fixed pricing terms (10 percent). Vendors must maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act (DSCSA) requirements.